nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—Renal tubular necrosis—Everolimus—kidney cancer	0.0319	0.0525	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Pazopanib—kidney cancer	0.0144	0.0237	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—IL2—kidney cancer	0.0116	0.4	CrCbGaD
Phenylpropanolamine—Hepatocellular injury—Everolimus—kidney cancer	0.0114	0.0187	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Erlotinib—kidney cancer	0.011	0.0181	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Sorafenib—kidney cancer	0.0099	0.0163	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Sunitinib—kidney cancer	0.00952	0.0157	CcSEcCtD
Phenylpropanolamine—Ephedrine—ACHE—kidney cancer	0.00909	0.312	CrCbGaD
Phenylpropanolamine—Irritability—Everolimus—kidney cancer	0.0079	0.013	CcSEcCtD
Phenylpropanolamine—Urinary retention—Everolimus—kidney cancer	0.00787	0.0129	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Paclitaxel—kidney cancer	0.00681	0.0112	CcSEcCtD
Phenylpropanolamine—Flushing—Pazopanib—kidney cancer	0.00673	0.0111	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Paclitaxel—kidney cancer	0.0064	0.0105	CcSEcCtD
Phenylpropanolamine—Vision blurred—Pazopanib—kidney cancer	0.00595	0.00978	CcSEcCtD
Phenylpropanolamine—Hallucination—Everolimus—kidney cancer	0.0057	0.00936	CcSEcCtD
Phenylpropanolamine—Anxiety—Temsirolimus—kidney cancer	0.00568	0.00934	CcSEcCtD
Phenylpropanolamine—Urinary retention—Vincristine—kidney cancer	0.00556	0.00914	CcSEcCtD
Phenylpropanolamine—Ataxia—Vincristine—kidney cancer	0.0055	0.00904	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Capecitabine—kidney cancer	0.00535	0.00879	CcSEcCtD
Phenylpropanolamine—Ephedrine—BCHE—kidney cancer	0.00535	0.184	CrCbGaD
Phenylpropanolamine—Flushing—Everolimus—kidney cancer	0.00531	0.00873	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Capecitabine—kidney cancer	0.00525	0.00863	CcSEcCtD
Phenylpropanolamine—Insomnia—Temsirolimus—kidney cancer	0.00495	0.00813	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Erlotinib—kidney cancer	0.00494	0.00811	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Temsirolimus—kidney cancer	0.00488	0.00801	CcSEcCtD
Phenylpropanolamine—Somnolence—Temsirolimus—kidney cancer	0.00486	0.00799	CcSEcCtD
Phenylpropanolamine—Vision blurred—Everolimus—kidney cancer	0.0047	0.00772	CcSEcCtD
Phenylpropanolamine—Constipation—Temsirolimus—kidney cancer	0.00468	0.00769	CcSEcCtD
Phenylpropanolamine—Tremor—Everolimus—kidney cancer	0.00467	0.00768	CcSEcCtD
Phenylpropanolamine—Insomnia—Pazopanib—kidney cancer	0.00466	0.00766	CcSEcCtD
Phenylpropanolamine—Flushing—Sorafenib—kidney cancer	0.00461	0.00758	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Pazopanib—kidney cancer	0.00459	0.00755	CcSEcCtD
Phenylpropanolamine—Agitation—Everolimus—kidney cancer	0.00458	0.00753	CcSEcCtD
Phenylpropanolamine—Somnolence—Pazopanib—kidney cancer	0.00458	0.00753	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Sorafenib—kidney cancer	0.00444	0.0073	CcSEcCtD
Phenylpropanolamine—Flushing—Sunitinib—kidney cancer	0.00444	0.00729	CcSEcCtD
Phenylpropanolamine—Ataxia—Paclitaxel—kidney cancer	0.00437	0.00718	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Sunitinib—kidney cancer	0.00427	0.00702	CcSEcCtD
Phenylpropanolamine—Anxiety—Everolimus—kidney cancer	0.00423	0.00695	CcSEcCtD
Phenylpropanolamine—Flushing—Dactinomycin—kidney cancer	0.0042	0.00691	CcSEcCtD
Phenylpropanolamine—Anxiety—Erlotinib—kidney cancer	0.00408	0.00671	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Temsirolimus—kidney cancer	0.00403	0.00662	CcSEcCtD
Phenylpropanolamine—Hallucination—Vincristine—kidney cancer	0.00402	0.00661	CcSEcCtD
Phenylpropanolamine—Liver injury—Doxorubicin—kidney cancer	0.00402	0.00661	CcSEcCtD
Phenylpropanolamine—Tachycardia—Everolimus—kidney cancer	0.00397	0.00653	CcSEcCtD
Phenylpropanolamine—Hypotension—Everolimus—kidney cancer	0.0038	0.00625	CcSEcCtD
Phenylpropanolamine—Insomnia—Everolimus—kidney cancer	0.00368	0.00605	CcSEcCtD
Phenylpropanolamine—Irritability—Capecitabine—kidney cancer	0.00364	0.00598	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Everolimus—kidney cancer	0.00363	0.00596	CcSEcCtD
Phenylpropanolamine—Urinary retention—Capecitabine—kidney cancer	0.00362	0.00596	CcSEcCtD
Phenylpropanolamine—Somnolence—Everolimus—kidney cancer	0.00362	0.00594	CcSEcCtD
Phenylpropanolamine—Dizziness—Temsirolimus—kidney cancer	0.00362	0.00594	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Doxorubicin—kidney cancer	0.0036	0.00592	CcSEcCtD
Phenylpropanolamine—Ataxia—Capecitabine—kidney cancer	0.00358	0.00589	CcSEcCtD
Phenylpropanolamine—Insomnia—Erlotinib—kidney cancer	0.00355	0.00583	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Erlotinib—kidney cancer	0.0035	0.00575	CcSEcCtD
Phenylpropanolamine—Constipation—Vinblastine—kidney cancer	0.00349	0.00574	CcSEcCtD
Phenylpropanolamine—Constipation—Everolimus—kidney cancer	0.00348	0.00572	CcSEcCtD
Phenylpropanolamine—Vomiting—Temsirolimus—kidney cancer	0.00348	0.00571	CcSEcCtD
Phenylpropanolamine—Rash—Temsirolimus—kidney cancer	0.00345	0.00567	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Doxorubicin—kidney cancer	0.00345	0.00566	CcSEcCtD
Phenylpropanolamine—Dermatitis—Temsirolimus—kidney cancer	0.00344	0.00566	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Gemcitabine—kidney cancer	0.00343	0.00563	CcSEcCtD
Phenylpropanolamine—Dizziness—Pazopanib—kidney cancer	0.00341	0.0056	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Doxorubicin—kidney cancer	0.00338	0.00556	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Vinblastine—kidney cancer	0.00337	0.00553	CcSEcCtD
Phenylpropanolamine—Constipation—Erlotinib—kidney cancer	0.00336	0.00552	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Everolimus—kidney cancer	0.00335	0.00551	CcSEcCtD
Phenylpropanolamine—Vomiting—Pazopanib—kidney cancer	0.00328	0.00538	CcSEcCtD
Phenylpropanolamine—Rash—Pazopanib—kidney cancer	0.00325	0.00534	CcSEcCtD
Phenylpropanolamine—Nausea—Temsirolimus—kidney cancer	0.00325	0.00534	CcSEcCtD
Phenylpropanolamine—Dermatitis—Pazopanib—kidney cancer	0.00325	0.00533	CcSEcCtD
Phenylpropanolamine—Agitation—Vincristine—kidney cancer	0.00324	0.00532	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Sorafenib—kidney cancer	0.00315	0.00517	CcSEcCtD
Phenylpropanolamine—Insomnia—Sunitinib—kidney cancer	0.00307	0.00505	CcSEcCtD
Phenylpropanolamine—Nausea—Pazopanib—kidney cancer	0.00306	0.00503	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP1A1—kidney cancer	0.00304	0.104	CrCbGaD
Phenylpropanolamine—Dyspnoea—Sunitinib—kidney cancer	0.00303	0.00498	CcSEcCtD
Phenylpropanolamine—Constipation—Sorafenib—kidney cancer	0.00302	0.00496	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vinblastine—kidney cancer	0.00301	0.00494	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Everolimus—kidney cancer	0.003	0.00493	CcSEcCtD
Phenylpropanolamine—Flushing—Paclitaxel—kidney cancer	0.00298	0.0049	CcSEcCtD
Phenylpropanolamine—Constipation—Sunitinib—kidney cancer	0.00291	0.00478	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Paclitaxel—kidney cancer	0.00287	0.00472	CcSEcCtD
Phenylpropanolamine—Tension—Paclitaxel—kidney cancer	0.00274	0.00451	CcSEcCtD
Phenylpropanolamine—Nervousness—Paclitaxel—kidney cancer	0.00272	0.00446	CcSEcCtD
Phenylpropanolamine—Dizziness—Vinblastine—kidney cancer	0.0027	0.00444	CcSEcCtD
Phenylpropanolamine—Dizziness—Everolimus—kidney cancer	0.00269	0.00442	CcSEcCtD
Phenylpropanolamine—Hypotension—Vincristine—kidney cancer	0.00269	0.00441	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Dactinomycin—kidney cancer	0.00265	0.00436	CcSEcCtD
Phenylpropanolamine—Vision blurred—Paclitaxel—kidney cancer	0.00264	0.00433	CcSEcCtD
Phenylpropanolamine—Tremor—Paclitaxel—kidney cancer	0.00262	0.00431	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Sorafenib—kidney cancer	0.0026	0.00428	CcSEcCtD
Phenylpropanolamine—Insomnia—Vincristine—kidney cancer	0.0026	0.00427	CcSEcCtD
Phenylpropanolamine—Vomiting—Vinblastine—kidney cancer	0.0026	0.00427	CcSEcCtD
Phenylpropanolamine—Dizziness—Erlotinib—kidney cancer	0.0026	0.00427	CcSEcCtD
Phenylpropanolamine—Vomiting—Everolimus—kidney cancer	0.00259	0.00425	CcSEcCtD
Phenylpropanolamine—Agitation—Paclitaxel—kidney cancer	0.00257	0.00422	CcSEcCtD
Phenylpropanolamine—Rash—Everolimus—kidney cancer	0.00256	0.00422	CcSEcCtD
Phenylpropanolamine—Dermatitis—Everolimus—kidney cancer	0.00256	0.00421	CcSEcCtD
Phenylpropanolamine—Hypotension—Gemcitabine—kidney cancer	0.00255	0.00419	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Sunitinib—kidney cancer	0.0025	0.00411	CcSEcCtD
Phenylpropanolamine—Vomiting—Erlotinib—kidney cancer	0.0025	0.0041	CcSEcCtD
Phenylpropanolamine—Rash—Erlotinib—kidney cancer	0.00247	0.00407	CcSEcCtD
Phenylpropanolamine—Dermatitis—Erlotinib—kidney cancer	0.00247	0.00406	CcSEcCtD
Phenylpropanolamine—Insomnia—Gemcitabine—kidney cancer	0.00247	0.00405	CcSEcCtD
Phenylpropanolamine—Constipation—Vincristine—kidney cancer	0.00246	0.00404	CcSEcCtD
Phenylpropanolamine—Flushing—Capecitabine—kidney cancer	0.00245	0.00402	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Gemcitabine—kidney cancer	0.00243	0.00399	CcSEcCtD
Phenylpropanolamine—Nausea—Vinblastine—kidney cancer	0.00243	0.00399	CcSEcCtD
Phenylpropanolamine—Somnolence—Gemcitabine—kidney cancer	0.00242	0.00398	CcSEcCtD
Phenylpropanolamine—Nausea—Everolimus—kidney cancer	0.00242	0.00397	CcSEcCtD
Phenylpropanolamine—Anxiety—Paclitaxel—kidney cancer	0.00237	0.0039	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Dactinomycin—kidney cancer	0.00237	0.00389	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Capecitabine—kidney cancer	0.00236	0.00387	CcSEcCtD
Phenylpropanolamine—Dizziness—Sorafenib—kidney cancer	0.00234	0.00384	CcSEcCtD
Phenylpropanolamine—Constipation—Gemcitabine—kidney cancer	0.00233	0.00383	CcSEcCtD
Phenylpropanolamine—Nausea—Erlotinib—kidney cancer	0.00233	0.00383	CcSEcCtD
Phenylpropanolamine—Ataxia—Doxorubicin—kidney cancer	0.00231	0.0038	CcSEcCtD
Phenylpropanolamine—Confusional state—Paclitaxel—kidney cancer	0.0023	0.00378	CcSEcCtD
Phenylpropanolamine—Dizziness—Sunitinib—kidney cancer	0.00225	0.00369	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Gemcitabine—kidney cancer	0.00225	0.00369	CcSEcCtD
Phenylpropanolamine—Vomiting—Sorafenib—kidney cancer	0.00225	0.00369	CcSEcCtD
Phenylpropanolamine—Tachycardia—Paclitaxel—kidney cancer	0.00223	0.00366	CcSEcCtD
Phenylpropanolamine—Rash—Sorafenib—kidney cancer	0.00223	0.00366	CcSEcCtD
Phenylpropanolamine—Dermatitis—Sorafenib—kidney cancer	0.00222	0.00366	CcSEcCtD
Phenylpropanolamine—Vision blurred—Capecitabine—kidney cancer	0.00216	0.00356	CcSEcCtD
Phenylpropanolamine—Vomiting—Sunitinib—kidney cancer	0.00216	0.00355	CcSEcCtD
Phenylpropanolamine—Tremor—Capecitabine—kidney cancer	0.00215	0.00353	CcSEcCtD
Phenylpropanolamine—Rash—Sunitinib—kidney cancer	0.00214	0.00352	CcSEcCtD
Phenylpropanolamine—Dermatitis—Sunitinib—kidney cancer	0.00214	0.00352	CcSEcCtD
Phenylpropanolamine—Hypotension—Paclitaxel—kidney cancer	0.00213	0.00351	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vincristine—kidney cancer	0.00212	0.00348	CcSEcCtD
Phenylpropanolamine—Nausea—Sorafenib—kidney cancer	0.0021	0.00345	CcSEcCtD
Phenylpropanolamine—Insomnia—Paclitaxel—kidney cancer	0.00206	0.00339	CcSEcCtD
Phenylpropanolamine—Vomiting—Dactinomycin—kidney cancer	0.00205	0.00336	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Paclitaxel—kidney cancer	0.00204	0.00334	CcSEcCtD
Phenylpropanolamine—Somnolence—Paclitaxel—kidney cancer	0.00203	0.00334	CcSEcCtD
Phenylpropanolamine—Rash—Dactinomycin—kidney cancer	0.00203	0.00333	CcSEcCtD
Phenylpropanolamine—Nausea—Sunitinib—kidney cancer	0.00202	0.00332	CcSEcCtD
Phenylpropanolamine—Constipation—Paclitaxel—kidney cancer	0.00195	0.00321	CcSEcCtD
Phenylpropanolamine—Anxiety—Capecitabine—kidney cancer	0.00195	0.0032	CcSEcCtD
Phenylpropanolamine—Nausea—Dactinomycin—kidney cancer	0.00191	0.00314	CcSEcCtD
Phenylpropanolamine—Dizziness—Vincristine—kidney cancer	0.0019	0.00312	CcSEcCtD
Phenylpropanolamine—Drowsiness—Doxorubicin—kidney cancer	0.00189	0.00311	CcSEcCtD
Phenylpropanolamine—Confusional state—Capecitabine—kidney cancer	0.00189	0.0031	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Paclitaxel—kidney cancer	0.00188	0.00309	CcSEcCtD
Phenylpropanolamine—Tachycardia—Capecitabine—kidney cancer	0.00183	0.003	CcSEcCtD
Phenylpropanolamine—Vomiting—Vincristine—kidney cancer	0.00183	0.003	CcSEcCtD
Phenylpropanolamine—Rash—Vincristine—kidney cancer	0.00181	0.00298	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vincristine—kidney cancer	0.00181	0.00298	CcSEcCtD
Phenylpropanolamine—Hypotension—Capecitabine—kidney cancer	0.00175	0.00288	CcSEcCtD
Phenylpropanolamine—Vomiting—Gemcitabine—kidney cancer	0.00173	0.00285	CcSEcCtD
Phenylpropanolamine—Rash—Gemcitabine—kidney cancer	0.00172	0.00283	CcSEcCtD
Phenylpropanolamine—Dermatitis—Gemcitabine—kidney cancer	0.00172	0.00282	CcSEcCtD
Phenylpropanolamine—Nausea—Vincristine—kidney cancer	0.00171	0.00281	CcSEcCtD
Phenylpropanolamine—Insomnia—Capecitabine—kidney cancer	0.00169	0.00278	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Paclitaxel—kidney cancer	0.00168	0.00276	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Capecitabine—kidney cancer	0.00167	0.00274	CcSEcCtD
Phenylpropanolamine—Nausea—Gemcitabine—kidney cancer	0.00162	0.00266	CcSEcCtD
Phenylpropanolamine—Constipation—Capecitabine—kidney cancer	0.0016	0.00263	CcSEcCtD
Phenylpropanolamine—Flushing—Doxorubicin—kidney cancer	0.00158	0.00259	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Capecitabine—kidney cancer	0.00154	0.00254	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Doxorubicin—kidney cancer	0.00152	0.0025	CcSEcCtD
Phenylpropanolamine—Dizziness—Paclitaxel—kidney cancer	0.00151	0.00248	CcSEcCtD
Phenylpropanolamine—Tension—Doxorubicin—kidney cancer	0.00145	0.00239	CcSEcCtD
Phenylpropanolamine—Vomiting—Paclitaxel—kidney cancer	0.00145	0.00239	CcSEcCtD
Phenylpropanolamine—Rash—Paclitaxel—kidney cancer	0.00144	0.00237	CcSEcCtD
Phenylpropanolamine—Dermatitis—Paclitaxel—kidney cancer	0.00144	0.00236	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—kidney cancer	0.00144	0.00236	CcSEcCtD
Phenylpropanolamine—Vision blurred—Doxorubicin—kidney cancer	0.00139	0.00229	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Capecitabine—kidney cancer	0.00138	0.00227	CcSEcCtD
Phenylpropanolamine—Agitation—Doxorubicin—kidney cancer	0.00136	0.00223	CcSEcCtD
Phenylpropanolamine—Nausea—Paclitaxel—kidney cancer	0.00136	0.00223	CcSEcCtD
Phenylpropanolamine—Anxiety—Doxorubicin—kidney cancer	0.00126	0.00206	CcSEcCtD
Phenylpropanolamine—Dizziness—Capecitabine—kidney cancer	0.00124	0.00204	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—kidney cancer	0.00122	0.002	CcSEcCtD
Phenylpropanolamine—Vomiting—Capecitabine—kidney cancer	0.00119	0.00196	CcSEcCtD
Phenylpropanolamine—Rash—Capecitabine—kidney cancer	0.00118	0.00194	CcSEcCtD
Phenylpropanolamine—Dermatitis—Capecitabine—kidney cancer	0.00118	0.00194	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—kidney cancer	0.00118	0.00194	CcSEcCtD
Phenylpropanolamine—Hypotension—Doxorubicin—kidney cancer	0.00113	0.00185	CcSEcCtD
Phenylpropanolamine—Nausea—Capecitabine—kidney cancer	0.00111	0.00183	CcSEcCtD
Phenylpropanolamine—Insomnia—Doxorubicin—kidney cancer	0.00109	0.00179	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Doxorubicin—kidney cancer	0.00108	0.00177	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—kidney cancer	0.00107	0.00176	CcSEcCtD
Phenylpropanolamine—Constipation—Doxorubicin—kidney cancer	0.00103	0.0017	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—kidney cancer	0.000995	0.00164	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—kidney cancer	0.00089	0.00146	CcSEcCtD
Phenylpropanolamine—Dizziness—Doxorubicin—kidney cancer	0.000798	0.00131	CcSEcCtD
Phenylpropanolamine—Vomiting—Doxorubicin—kidney cancer	0.000768	0.00126	CcSEcCtD
Phenylpropanolamine—Rash—Doxorubicin—kidney cancer	0.000761	0.00125	CcSEcCtD
Phenylpropanolamine—Dermatitis—Doxorubicin—kidney cancer	0.000761	0.00125	CcSEcCtD
Phenylpropanolamine—Nausea—Doxorubicin—kidney cancer	0.000717	0.00118	CcSEcCtD
Phenylpropanolamine—CYP1A2—Metabolism—SLC5A3—kidney cancer	0.00011	0.000305	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PGK1—kidney cancer	0.00011	0.000305	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—JUNB—kidney cancer	0.00011	0.000304	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PAK1—kidney cancer	0.00011	0.000304	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CTNNA1—kidney cancer	0.00011	0.000303	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HSPB1—kidney cancer	0.000109	0.000301	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EIF4EBP1—kidney cancer	0.000109	0.000301	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LDHB—kidney cancer	0.000108	0.000299	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—BCHE—kidney cancer	0.000107	0.000295	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—SLC5A5—kidney cancer	0.000105	0.000291	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—POMC—kidney cancer	0.000104	0.000287	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF2—kidney cancer	0.000102	0.000282	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CTNNA1—kidney cancer	0.000102	0.000281	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—SLC2A1—kidney cancer	0.000102	0.000281	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN2B—kidney cancer	0.000102	0.000281	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—POMC—kidney cancer	0.000102	0.00028	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PSMD7—kidney cancer	0.000101	0.00028	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TSC1—kidney cancer	0.000101	0.00028	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ANXA1—kidney cancer	0.000101	0.00028	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EIF4EBP1—kidney cancer	0.000101	0.00028	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HSPB1—kidney cancer	0.000101	0.00028	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—IL2—kidney cancer	0.000101	0.000278	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1R—kidney cancer	9.89e-05	0.000273	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FLT1—kidney cancer	9.82e-05	0.000271	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—RAF1—kidney cancer	9.53e-05	0.000263	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ANXA1—kidney cancer	9.42e-05	0.00026	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSC1—kidney cancer	9.42e-05	0.00026	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PSMD7—kidney cancer	9.42e-05	0.00026	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—IL2—kidney cancer	9.41e-05	0.00026	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CA9—kidney cancer	9.39e-05	0.000259	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—POMC—kidney cancer	9.26e-05	0.000255	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF2—kidney cancer	9.19e-05	0.000254	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	9.17e-05	0.000253	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN2B—kidney cancer	9.15e-05	0.000253	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FLT1—kidney cancer	9.12e-05	0.000252	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PAK1—kidney cancer	9.1e-05	0.000251	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JUNB—kidney cancer	9.1e-05	0.000251	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF2—kidney cancer	8.99e-05	0.000248	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN2B—kidney cancer	8.96e-05	0.000247	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1R—kidney cancer	8.89e-05	0.000245	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1R—kidney cancer	8.7e-05	0.00024	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—POMC—kidney cancer	8.6e-05	0.000237	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—RAF1—kidney cancer	8.57e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VEGFA—kidney cancer	8.55e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL2—kidney cancer	8.54e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTP1—kidney cancer	8.5e-05	0.000234	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—IL2—kidney cancer	8.46e-05	0.000233	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JUNB—kidney cancer	8.45e-05	0.000233	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PAK1—kidney cancer	8.45e-05	0.000233	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—POMC—kidney cancer	8.41e-05	0.000232	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—RAF1—kidney cancer	8.38e-05	0.000231	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—IL2—kidney cancer	8.27e-05	0.000228	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—POMC—kidney cancer	8.26e-05	0.000228	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HIF1A—kidney cancer	8.14e-05	0.000225	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TSC2—kidney cancer	8.12e-05	0.000224	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—MAPK3—kidney cancer	8.09e-05	0.000223	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ABCB1—kidney cancer	8.04e-05	0.000222	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CRABP1—kidney cancer	7.98e-05	0.00022	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—POMC—kidney cancer	7.81e-05	0.000216	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTM1—kidney cancer	7.81e-05	0.000215	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KDR—kidney cancer	7.79e-05	0.000215	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—MAPK1—kidney cancer	7.7e-05	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL2—kidney cancer	7.68e-05	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL2—kidney cancer	7.51e-05	0.000207	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF2—kidney cancer	7.44e-05	0.000205	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ITPR2—kidney cancer	7.42e-05	0.000205	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN2B—kidney cancer	7.41e-05	0.000204	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP1A1—kidney cancer	7.4e-05	0.000204	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HIF1A—kidney cancer	7.32e-05	0.000202	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TSC2—kidney cancer	7.3e-05	0.000201	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—KRAS—kidney cancer	7.27e-05	0.000201	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1R—kidney cancer	7.19e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APC—kidney cancer	7.17e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KIT—kidney cancer	7.17e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HIF1A—kidney cancer	7.16e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TSC2—kidney cancer	7.14e-05	0.000197	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KDR—kidney cancer	7e-05	0.000193	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—RAF1—kidney cancer	6.93e-05	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF2—kidney cancer	6.91e-05	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN2B—kidney cancer	6.88e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—MAPK3—kidney cancer	6.87e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KDR—kidney cancer	6.85e-05	0.000189	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—IL2—kidney cancer	6.84e-05	0.000189	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.84e-05	0.000189	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—POMC—kidney cancer	6.83e-05	0.000188	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTT1—kidney cancer	6.77e-05	0.000187	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ACHE—kidney cancer	6.77e-05	0.000187	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—BRAF—kidney cancer	6.74e-05	0.000186	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1R—kidney cancer	6.68e-05	0.000184	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PIK3CA—kidney cancer	6.68e-05	0.000184	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—kidney cancer	6.59e-05	0.000182	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—MAPK1—kidney cancer	6.54e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—kidney cancer	6.46e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APC—kidney cancer	6.45e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KIT—kidney cancer	6.45e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—RAF1—kidney cancer	6.44e-05	0.000178	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SCARB1—kidney cancer	6.4e-05	0.000177	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—IL2—kidney cancer	6.36e-05	0.000175	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS1—kidney cancer	6.34e-05	0.000175	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KIT—kidney cancer	6.31e-05	0.000174	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APC—kidney cancer	6.31e-05	0.000174	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—PIK3CA—kidney cancer	6.24e-05	0.000172	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PSMD7—kidney cancer	6.22e-05	0.000172	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL2—kidney cancer	6.21e-05	0.000171	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—MAPK3—kidney cancer	6.17e-05	0.00017	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—KRAS—kidney cancer	6.17e-05	0.00017	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—POMC—kidney cancer	6.14e-05	0.000169	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—BRAF—kidney cancer	6.06e-05	0.000167	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—MAPK3—kidney cancer	6.04e-05	0.000167	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—POMC—kidney cancer	6e-05	0.000166	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—BRAF—kidney cancer	5.93e-05	0.000164	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	5.92e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TSC2—kidney cancer	5.91e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—BCHE—kidney cancer	5.89e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—MAPK1—kidney cancer	5.88e-05	0.000162	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC5A5—kidney cancer	5.82e-05	0.000161	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL2—kidney cancer	5.77e-05	0.000159	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—MAPK1—kidney cancer	5.75e-05	0.000159	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTEN—kidney cancer	5.75e-05	0.000159	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PIK3CA—kidney cancer	5.67e-05	0.000156	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KDR—kidney cancer	5.66e-05	0.000156	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RAF1—kidney cancer	5.63e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A1—kidney cancer	5.62e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PIK3CA—kidney cancer	5.61e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RELA—kidney cancer	5.6e-05	0.000155	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB2—kidney cancer	5.57e-05	0.000154	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KRAS—kidney cancer	5.55e-05	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—POMC—kidney cancer	5.52e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	5.5e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MTOR—kidney cancer	5.5e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	5.49e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSC2—kidney cancer	5.49e-05	0.000151	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.46e-05	0.000151	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—kidney cancer	5.43e-05	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KDR—kidney cancer	5.26e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KIT—kidney cancer	5.22e-05	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APC—kidney cancer	5.22e-05	0.000144	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1B—kidney cancer	5.16e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	5.1e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RAF1—kidney cancer	5.06e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2—kidney cancer	5.05e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RELA—kidney cancer	5.04e-05	0.000139	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB2—kidney cancer	5.01e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	5e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	4.99e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—POMC—kidney cancer	4.97e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RAF1—kidney cancer	4.95e-05	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MTOR—kidney cancer	4.94e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RELA—kidney cancer	4.93e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—kidney cancer	4.92e-05	0.000136	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—JUN—kidney cancer	4.91e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BRAF—kidney cancer	4.9e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB2—kidney cancer	4.9e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CTNNB1—kidney cancer	4.87e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KIT—kidney cancer	4.85e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APC—kidney cancer	4.85e-05	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MTOR—kidney cancer	4.83e-05	0.000133	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.76e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	4.75e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTEN—kidney cancer	4.75e-05	0.000131	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—kidney cancer	4.69e-05	0.000129	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	4.64e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	4.64e-05	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—POMC—kidney cancer	4.61e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BRAF—kidney cancer	4.56e-05	0.000126	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	4.54e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2—kidney cancer	4.54e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	4.54e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	4.49e-05	0.000124	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—kidney cancer	4.44e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2—kidney cancer	4.44e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—kidney cancer	4.42e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	4.42e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—JUN—kidney cancer	4.41e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—kidney cancer	4.4e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	4.38e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—kidney cancer	4.33e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—JUN—kidney cancer	4.32e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—kidney cancer	4.31e-05	0.000119	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—kidney cancer	4.29e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	4.28e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTEN—kidney cancer	4.27e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	4.22e-05	0.000116	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTEN—kidney cancer	4.18e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	4.17e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	4.13e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	4.09e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP1A1—kidney cancer	4.09e-05	0.000113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RELA—kidney cancer	4.08e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK3—kidney cancer	4.06e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CA—kidney cancer	4.05e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	4.05e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	4e-05	0.00011	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—kidney cancer	3.95e-05	0.000109	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK1—kidney cancer	3.86e-05	0.000107	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—kidney cancer	3.86e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTEN—kidney cancer	3.84e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	3.83e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RAF1—kidney cancer	3.8e-05	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RELA—kidney cancer	3.79e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—kidney cancer	3.77e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	3.76e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	3.75e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MTOR—kidney cancer	3.71e-05	0.000102	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2—kidney cancer	3.67e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK3—kidney cancer	3.65e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—kidney cancer	3.65e-05	0.000101	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	3.58e-05	9.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JUN—kidney cancer	3.57e-05	9.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK3—kidney cancer	3.57e-05	9.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—kidney cancer	3.55e-05	9.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	3.54e-05	9.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	3.49e-05	9.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK1—kidney cancer	3.47e-05	9.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—kidney cancer	3.47e-05	9.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	3.45e-05	9.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2—kidney cancer	3.41e-05	9.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK1—kidney cancer	3.4e-05	9.37e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.36e-05	9.26e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CA—kidney cancer	3.35e-05	9.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—kidney cancer	3.33e-05	9.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JUN—kidney cancer	3.32e-05	9.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	3.29e-05	9.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—kidney cancer	3.28e-05	9.04e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—kidney cancer	3.24e-05	8.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTEN—kidney cancer	3.21e-05	8.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—kidney cancer	3.21e-05	8.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	3.12e-05	8.61e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—POMC—kidney cancer	3.05e-05	8.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	3.01e-05	8.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	2.95e-05	8.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	2.95e-05	8.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—kidney cancer	2.91e-05	8.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	2.9e-05	8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—kidney cancer	2.87e-05	7.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—kidney cancer	2.85e-05	7.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	2.81e-05	7.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	2.74e-05	7.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CA—kidney cancer	2.71e-05	7.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—kidney cancer	2.67e-05	7.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	2.65e-05	7.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	2.61e-05	7.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—kidney cancer	2.46e-05	6.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	2.44e-05	6.72e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—kidney cancer	2.43e-05	6.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—kidney cancer	2.36e-05	6.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	2.26e-05	6.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—kidney cancer	2.19e-05	6.04e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTEN—kidney cancer	2.12e-05	5.85e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.49e-05	4.12e-05	CbGpPWpGaD
